Innate Pharma SA (IPH)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8014384)
◆英語タイトル:Innate Pharma SA (IPH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014384
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:53
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Innate Pharma SA (Innate Pharma) is a healthcare products provider that develops immunopharmacology and antibody technology products. The company carries out the discovery and development of therapeutic antibodies for the treatment of cancer and inflammatory diseases. It develops new monoclonal antibodies that targets receptors and pathways in controlling the activation of innate immunity cells. The company’s pipeline products comprise lirilumab, monalizumab, IPH4102, IPH4301, IPH52, IPH53 and IPH33. It has collaborations and partnerships with academic laboratories, clinical centers and industrial leaders. It Innate Pharma is headquartered in Marseille, France.

Innate Pharma SA (IPH) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Innate Pharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Innate Pharma SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Innate Pharma SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Innate Pharma SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Innate Pharma SA, Medical Devices Deals, 2011 to YTD 2017 10
Innate Pharma SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Innate Pharma SA, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Institut Paoli-Calmettes Enters into Research Collaboration with Innate Pharma 12
Innate Pharma Enters into Co-Development Agreement with AstraZeneca for Immuno-Oncology 13
Innate Pharma Enters into Agreement with Sanofi for Next Generation Antibody-Drug Conjugates 14
Licensing Agreements 15
Innate Pharma Enters into Licensing Agreement with Novo Nordisk 15
Innate Pharma Enters into Licensing Agreement with Orega Biotech 16
Sanofi Enters into Licensing Agreement with Innate Pharma 17
Innate Pharma Enters Into Licensing Agreement With Novo Nordisk 18
Bristol-Myers Squibb Enters Into Licensing Agreement With Innate Pharma For IPH2102 20
Equity Offering 22
Innate Pharma Raises USD68 Million in Private Placement of Shares 22
Innate Pharma Completes Private Placement Of Shares For US$27.4 Million 23
Innate Pharma SA – Key Competitors 25
Innate Pharma SA – Key Employees 26
Innate Pharma SA – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Nov 15, 2017: INNATE PHARMA: Third quarter 2017 report 28
Sep 18, 2017: First Half Of 2017: Delivering Key Clinical Data And Strengthening The Pipeline 29
Sep 18, 2017: Innate Pharma: First half of 2017: delivering key clinical data and strengthening the pipeline 32
May 15, 2017: Innate Pharma: First quarter 2017 report 33
Mar 07, 2017: Innate Pharma: 2016: Operational progress and robust financial position for further growth 34
Nov 03, 2016: INNATE PHARMA : Third Quarter 2016 Report 35
Sep 08, 2016: First Half Of 2016: Building Momentum Through Clinical Development And New Partnerships 36
May 04, 2016: Innate Pharma First Quarter 2016 Report 37
Feb 18, 2016: Innate harma: Financial Results 2015 38
Corporate Communications 41
Dec 19, 2016: INNATE PHARMA announces key leadership and corporate governance changes to support next stage of development 41
Product News 42
04/18/2016: Innate Pharma presents new CD73 checkpoint inhibitor program 42
Clinical Trials 43
Sep 11, 2017: Innate Pharma Presents New Preclinical Data For IPH5401 at 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy conference 43
Jun 05, 2016: ASCO 2016: Phase I study protocol investigating IPH4102 in cutaneous T-Cell lymphomas 44
Apr 19, 2016: INNATE PHARMA: First-in-class CD39 checkpoint inhibitor presented at the AACR meeting 45
Apr 18, 2016: INNATE PHARMA: New preclinical data further supporting the development of IPH4301 presented at the AACR meeting 46
Apr 18, 2016: New data presented at AACR support the rationale for combination treatment with monalizumab and durvalumab 47
Mar 17, 2016: AACR 2016: Innate Pharma displays broad innovative pipeline in immuno-oncology 49
Feb 08, 2016: INNATE PHARMA : Start of Phase I clinical trial of monalizumab in combination with durvalumab 51
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53

List of Tables
Innate Pharma SA, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Innate Pharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Innate Pharma SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Innate Pharma SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Innate Pharma SA, Deals By Therapy Area, 2011 to YTD 2017 9
Innate Pharma SA, Medical Devices Deals, 2011 to YTD 2017 10
Innate Pharma SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Institut Paoli-Calmettes Enters into Research Collaboration with Innate Pharma 12
Innate Pharma Enters into Co-Development Agreement with AstraZeneca for Immuno-Oncology 13
Innate Pharma Enters into Agreement with Sanofi for Next Generation Antibody-Drug Conjugates 14
Innate Pharma Enters into Licensing Agreement with Novo Nordisk 15
Innate Pharma Enters into Licensing Agreement with Orega Biotech 16
Sanofi Enters into Licensing Agreement with Innate Pharma 17
Innate Pharma Enters Into Licensing Agreement With Novo Nordisk 18
Bristol-Myers Squibb Enters Into Licensing Agreement With Innate Pharma For IPH2102 20
Innate Pharma Raises USD68 Million in Private Placement of Shares 22
Innate Pharma Completes Private Placement Of Shares For US$27.4 Million 23
Innate Pharma SA, Key Competitors 25
Innate Pharma SA, Key Employees 26
Innate Pharma SA, Subsidiaries 27

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Innate Pharma SA (IPH)-製薬・医療分野:企業M&A・提携分析(Innate Pharma SA (IPH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆